FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034134614> ?p ?o ?g. }

• W2034134614 endingPage "558" @default.
• W2034134614 startingPage "550" @default.
• W2034134614 abstract "Background Epidemiologic data for cardiac abnormality predating decreased kidney function are sparse. We investigated the associations of high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro–brain natriuretic peptide (NT-proBNP) with end-stage renal disease (ESRD) risk in a community-based cohort. Study Design A prospective cohort study. Setting & Participants 10,749 white and black participants at the fourth visit (1996-1998) of the Atherosclerosis Risk in Communities (ARIC) Study with follow-up through 2010. Predictor hs-cTnT (3, 6, 9, and 14 ng/L) and NT-proBNP (41.6, 81.0, 142.5, and 272.5 pg/mL) levels were divided into 5 categories at the same percentiles (32th, 57th, 77th, and 91th; corresponding to ordinary thresholds of hs-cTnT), with the lowest category as a reference. Outcomes Incident ESRD defined as initiation of dialysis therapy, transplantation, or death due to kidney disease. Measurements Relative risk and risk prediction of ESRD according to hs-cTnT and NT-proBNP levels based on Cox proportional hazards models. Results During a median follow-up of 13.1 years, 235 participants developed ESRD (1.8 cases/1,000 person-years). hs-cTnT and NT-proBNP levels were associated with ESRD risk independently of each other and of potential confounders, including kidney function and albuminuria (adjusted HRs for highest category, 4.43 [95% CI, 2.43-8.09] and 2.28 [95% CI, 1.44-3.60], respectively). For hs-cTnT level, the association was significant even at the third category (HR for 6-8 ng/L of hs-cTnT, 2.74 [95% CI, 1.54-4.88]). Their associations were largely consistent even among persons without decreased kidney function or history of cardiovascular disease. hs-cTnT and NT-proBNP levels both significantly improved ESRD prediction (C statistic differences of 0.0084 [95% CI, 0.0005-0.0164] and 0.0045 [95% CI, 0.0004-0.0087], respectively, from 0.884 with conventional risk factors). Limitations Relatively small number of ESRD cases and single measurement of hs-cTnT and NT-proBNP. Conclusions hs-cTnT and NT-proBNP levels independently predicted ESRD risk in the general population, with more evident results for hs-cTnT. These results suggest the involvement of cardiac abnormality, particularly cardiac injury, in the progression of reduced kidney function and/or may reflect the useful property of hs-cTnT as an end-organ damage marker. Epidemiologic data for cardiac abnormality predating decreased kidney function are sparse. We investigated the associations of high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro–brain natriuretic peptide (NT-proBNP) with end-stage renal disease (ESRD) risk in a community-based cohort. A prospective cohort study. 10,749 white and black participants at the fourth visit (1996-1998) of the Atherosclerosis Risk in Communities (ARIC) Study with follow-up through 2010. hs-cTnT (3, 6, 9, and 14 ng/L) and NT-proBNP (41.6, 81.0, 142.5, and 272.5 pg/mL) levels were divided into 5 categories at the same percentiles (32th, 57th, 77th, and 91th; corresponding to ordinary thresholds of hs-cTnT), with the lowest category as a reference. Incident ESRD defined as initiation of dialysis therapy, transplantation, or death due to kidney disease. Relative risk and risk prediction of ESRD according to hs-cTnT and NT-proBNP levels based on Cox proportional hazards models. During a median follow-up of 13.1 years, 235 participants developed ESRD (1.8 cases/1,000 person-years). hs-cTnT and NT-proBNP levels were associated with ESRD risk independently of each other and of potential confounders, including kidney function and albuminuria (adjusted HRs for highest category, 4.43 [95% CI, 2.43-8.09] and 2.28 [95% CI, 1.44-3.60], respectively). For hs-cTnT level, the association was significant even at the third category (HR for 6-8 ng/L of hs-cTnT, 2.74 [95% CI, 1.54-4.88]). Their associations were largely consistent even among persons without decreased kidney function or history of cardiovascular disease. hs-cTnT and NT-proBNP levels both significantly improved ESRD prediction (C statistic differences of 0.0084 [95% CI, 0.0005-0.0164] and 0.0045 [95% CI, 0.0004-0.0087], respectively, from 0.884 with conventional risk factors). Relatively small number of ESRD cases and single measurement of hs-cTnT and NT-proBNP. hs-cTnT and NT-proBNP levels independently predicted ESRD risk in the general population, with more evident results for hs-cTnT. These results suggest the involvement of cardiac abnormality, particularly cardiac injury, in the progression of reduced kidney function and/or may reflect the useful property of hs-cTnT as an end-organ damage marker." @default.
• W2034134614 created "2016-06-24" @default.
• W2034134614 creator A5028237471 @default.
• W2034134614 creator A5033395115 @default.
• W2034134614 creator A5038371805 @default.
• W2034134614 creator A5048938940 @default.
• W2034134614 creator A5052604218 @default.
• W2034134614 creator A5054830306 @default.
• W2034134614 creator A5074978138 @default.
• W2034134614 creator A5086558284 @default.
• W2034134614 creator A5089845058 @default.
• W2034134614 date "2015-04-01" @default.
• W2034134614 modified "2023-09-30" @default.
• W2034134614 title "Association of High-Sensitivity Cardiac Troponin T and Natriuretic Peptide With Incident ESRD: The Atherosclerosis Risk in Communities (ARIC) Study" @default.
• W2034134614 cites W1416197530 @default.
• W2034134614 cites W14875219 @default.
• W2034134614 cites W149118906 @default.
• W2034134614 cites W1570583414 @default.
• W2034134614 cites W1834143950 @default.
• W2034134614 cites W1979458610 @default.
• W2034134614 cites W1989339035 @default.
• W2034134614 cites W1998943227 @default.
• W2034134614 cites W2004231157 @default.
• W2034134614 cites W2005228303 @default.
• W2034134614 cites W2009826381 @default.
• W2034134614 cites W2013355784 @default.
• W2034134614 cites W2021232559 @default.
• W2034134614 cites W2023019521 @default.
• W2034134614 cites W2031930369 @default.
• W2034134614 cites W2033675250 @default.
• W2034134614 cites W2033803279 @default.
• W2034134614 cites W2038981426 @default.
• W2034134614 cites W2040273911 @default.
• W2034134614 cites W2043609912 @default.
• W2034134614 cites W2053293745 @default.
• W2034134614 cites W2055534323 @default.
• W2034134614 cites W2055663701 @default.
• W2034134614 cites W2063007022 @default.
• W2034134614 cites W2070532065 @default.
• W2034134614 cites W2081170476 @default.
• W2034134614 cites W2081231656 @default.
• W2034134614 cites W2082803399 @default.
• W2034134614 cites W2088000704 @default.
• W2034134614 cites W2092433795 @default.
• W2034134614 cites W2102556842 @default.
• W2034134614 cites W2104239833 @default.
• W2034134614 cites W2110182057 @default.
• W2034134614 cites W2115931410 @default.
• W2034134614 cites W2120309176 @default.
• W2034134614 cites W2128233866 @default.
• W2034134614 cites W2130771083 @default.
• W2034134614 cites W2132517877 @default.
• W2034134614 cites W2138098508 @default.
• W2034134614 cites W2145632027 @default.
• W2034134614 cites W2153030306 @default.
• W2034134614 cites W2155655418 @default.
• W2034134614 cites W2155965977 @default.
• W2034134614 cites W2158789287 @default.
• W2034134614 cites W2165817472 @default.
• W2034134614 cites W2166727347 @default.
• W2034134614 cites W2170921938 @default.
• W2034134614 cites W2181350280 @default.
• W2034134614 cites W2475261460 @default.
• W2034134614 cites W2580449060 @default.
• W2034134614 cites W2584947097 @default.
• W2034134614 cites W2605975631 @default.
• W2034134614 cites W2607031541 @default.
• W2034134614 cites W2912227678 @default.
• W2034134614 cites W49657269 @default.
• W2034134614 doi "https://doi.org/10.1053/j.ajkd.2014.08.021" @default.
• W2034134614 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4369179" @default.
• W2034134614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25446023" @default.
• W2034134614 hasPublicationYear "2015" @default.
• W2034134614 type Work @default.
• W2034134614 sameAs 2034134614 @default.
• W2034134614 citedByCount "14" @default.
• W2034134614 countsByYear W20341346142015 @default.
• W2034134614 countsByYear W20341346142016 @default.
• W2034134614 countsByYear W20341346142017 @default.
• W2034134614 countsByYear W20341346142018 @default.
• W2034134614 countsByYear W20341346142019 @default.
• W2034134614 countsByYear W20341346142020 @default.
• W2034134614 countsByYear W20341346142021 @default.
• W2034134614 countsByYear W20341346142023 @default.
• W2034134614 crossrefType "journal-article" @default.
• W2034134614 hasAuthorship W2034134614A5028237471 @default.
• W2034134614 hasAuthorship W2034134614A5033395115 @default.
• W2034134614 hasAuthorship W2034134614A5038371805 @default.
• W2034134614 hasAuthorship W2034134614A5048938940 @default.
• W2034134614 hasAuthorship W2034134614A5052604218 @default.
• W2034134614 hasAuthorship W2034134614A5054830306 @default.
• W2034134614 hasAuthorship W2034134614A5074978138 @default.
• W2034134614 hasAuthorship W2034134614A5086558284 @default.
• W2034134614 hasAuthorship W2034134614A5089845058 @default.
• W2034134614 hasBestOaLocation W20341346142 @default.
• W2034134614 hasConcept C126322002 @default.
• W2034134614 hasConcept C144469398 @default.
• W2034134614 hasConcept C159641895 @default.

• next